CSTB Antibody | 19-170

CSTB Antibody | 19-170 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-98 of human CSTB (NP_000091.1) .

Research Area: Cell Cycle

Tested Application: WB, IHC, IF

Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
IF: 1:50 - 1:200

Specificiy: N/A

Positive Control 1: HepG2

Positive Control 2: SW480

Positive Control 3: DU145

Positive Control 4: A-549

Positive Control 5: A-431

Positive Control 6: MCF7

Molecular Weight: Observed: 14kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: CSTB, CST6, EPM1, PME, STFB, ULD, EPM1A

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins) , type 2 cystatins and kininogens. This gene encodes a stefin that functions as an intracellular thiol protease inhibitor. The protein is able to form a dimer stabilized by noncovalent forces, inhibiting papain and cathepsins l, h and b. The protein is thought to play a role in protecting against the proteases leaking from lysosomes. Evidence indicates that mutations in this gene are responsible for the primary defects in patients with progressive myoclonic epilepsy (EPM1) . One type of mutation responsible for EPM1 is the expansion in the promoter region of this gene of a CCCCGCCCCGCG repeat from 2-3 copies to 30-78 copies.